Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Stock Has Average Target Price of $15.62 According to Analysts

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) has received a consensus recommendation of “Hold” from the four ratings firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and two have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $8.33.

A number of brokerages have recently issued reports on ADIL. Alliance Global Partners began coverage on Adial Pharmaceuticals in a research note on Monday, August 3rd. They issued a “buy” rating and a $11.00 price objective on the stock. Wall Street Zen raised Adial Pharmaceuticals to a “sell” rating in a research note on Saturday, August 15th. Loop Capital set a $6.00 target price on Adial Pharmaceuticals in a report on Monday, June 15th. Brookline Capital Markets downgraded Adial Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Finally, Weiss Ratings raised Adial Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 24th.

Insider Buying and Selling at Adial Pharmaceuticals

In related news, major shareholder Coastlands Capital Lp acquired 10,053 shares of the stock in a transaction dated Thursday, July 9th. The stock was bought at an average price of $2.79 per share, for a total transaction of $28,047.87. Following the purchase, the insider directly owned 383,375 shares of the company’s stock, valued at $1,069,616.25. The trade was a 2.69% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 8.00% of the stock is owned by corporate insiders.

Adial Pharmaceuticals Stock Up 2.7%

Shares of NASDAQ ADIL opened at $4.15 on Wednesday. Adial Pharmaceuticals has a twelve month low of $1.31 and a twelve month high of $10.75. The firm has a fifty day simple moving average of $4.78 and a 200 day simple moving average of $3.05. The company has a market capitalization of $10.90 million, a PE ratio of -0.28 and a beta of 1.38.

Adial Pharmaceuticals (NASDAQ:ADIL) last released its earnings results on Friday, August 14th. The company reported ($11.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by ($10.22).

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for addiction and related disorders. The company’s primary focus is alcohol use disorder, a chronic condition characterized by problematic alcohol consumption and difficulty reducing or stopping use.

Adial’s lead investigational product, AD04, is an oral, genetically targeted therapy based on ondansetron, a selective serotonin-3 receptor antagonist. The company is studying AD04 as a potential treatment for alcohol use disorder in patients identified through genetic or biomarker-based testing.